Headlines
-
SIG confident of strategy
Friday | Mar 23 2018SIGMA Healthcare says 2017/18 was a "challenging year" during which it continued to execute its long term strategy despite declining sales due to softening consumer sentiment and reduced demand for low-margin Hepatitis C drugs.
-
Guild stresses impartiality
Thursday | Mar 22 2018THE Pharmacy Guild of Australia's approach to politics is "non-partisan and focused on aligning the mutual interests of its community pharmacy members with those of the government, which is tasked with representing the interests of consumers," says Guild executive director David Quilty writing in Forefront this week.
-
Pharmacy e-security alert
Thursday | Mar 22 2018CHANGES to Australia's Data Breach Notification Laws which became effective last month have significant implications for Australian pharmacy businesses, according to Giuseppe Carollo from pharmacy insurance specialist Carollo Horton.
-
GP pharmacists trial success
Wednesday | Mar 21 2018PHARMACISTS have a valuable role to play in the detection and resolution of drug-related problems as part of a general practice team, according to a new study based on the outcomes of a six month trial in Western Sydney.
-
Generic headaches grow
Wednesday | Mar 21 2018AS IF pharmaceutical brand originators didn't have enough to worry about with generic copies of their drugs, now it appears that the brand originator can get into trouble when a generic causes harm that had not been identified and warned about by the original research company.
-
NZ pharmacy consultation
Tuesday | Mar 20 2018AUTHORITIES in New Zealand are seeking input from pharmacy owners, pharmacists and the public on opportunities for pharmacist services in local communities.
-
PIES for pharmacy interns
Tuesday | Mar 20 2018THE Pharmacy Board of Australia (PBA) has launched a large scale survey of recent pharmacy interns and preceptors across Australia, known as the Pharmacy Internship Experience Survey (PIES).
-
Zinbryta withdrawal
Monday | Mar 19 2018CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).
-
Apr PBS price cuts flagged
Monday | Mar 19 2018THE Pharmacy Guild says there are a number of "significant price reductions" on the general, chemotherapy and S100 Pharmaceutical Benefits Scheme schedules for Apr 2018.
-
MHR guidelines finalised
Friday | Mar 16 2018THE Pharmaceutical Society of Australia has announced the completion of the PSA My Health Record Guidelines for Pharmacists, with the document to be formally launched in Canberra on 11 Apr.